3 results
* to describe the safety profile for qW, q2W and q3W regimens. * to determine the Maximum Tolerated Dose (MTD), if achieved (all regimens)* to describe the pharmacokinetics (PK) of single-agent RO6895882. Substudy BP28920/IMGThe study is designed to…
The primary outcome parameter is the Gout Activity Score (GAS)after 6 months of rasburicase treatment. Secondary outcome parameters are the serum uric acid concentration, the clinical evaluation of tophus load, patient reported outcomes: MD-HAQ, GAQ…
We aim to determine the specificity of radiolabelled exendin during the course of T2D and to examine the role of glycemic control on the correlation between pancreatic 111In-exendin uptake, BCM and GLP-1R expression in patients with T2D undergoing (…